Back to top
more

Entrada Therapeutics (TRDA)

(Delayed Data from NSDQ)

$5.30 USD

5.30
498,972

-0.65 (-10.92%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $5.28 -0.02 (-0.38%) 6:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong

by Zacks Equity Research

Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.

Zacks Equity Research

Collegium (COLL) Shares Rise on Financial Outlook for 2024

by Zacks Equity Research

Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.

Zacks Equity Research

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO

by Zacks Equity Research

Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.

Zacks Equity Research

Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.

Zacks Equity Research

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

by Zacks Equity Research

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

Zacks Equity Research

BEAM Stock Rallies More Than 25% in 3 Months: What Next?

by Zacks Equity Research

BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.

Zacks Equity Research

Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology

by Zacks Equity Research

Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.

Zacks Equity Research

Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?

by Zacks Equity Research

Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.

Zacks Equity Research

Amicus (FOLD) Banks on Galafold, Overdependence a Concern

by Zacks Equity Research

Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.

Zacks Equity Research

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

by Zacks Equity Research

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Zacks Equity Research

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

by Zacks Equity Research

The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.

Zacks Equity Research

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

by Zacks Equity Research

The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

Zacks Equity Research

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

by Zacks Equity Research

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Zacks Equity Research

Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal

by Zacks Equity Research

Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.

Zacks Equity Research

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

by Zacks Equity Research

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.

Zacks Equity Research

argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study

by Zacks Equity Research

argenx's (ARGX) phase III ADDRESS study, evaluating efgartigimod subcutaneous for treating pemphigus, fails to meet primary and secondary endpoints. Stock falls.

Zacks Equity Research

bluebird (BLUE) Stock Down on Raising Additional Capital

by Zacks Equity Research

bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.

Zacks Equity Research

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.

Zacks Equity Research

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

by Zacks Equity Research

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Zacks Equity Research

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

by Zacks Equity Research

Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.

Zacks Equity Research

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

by Zacks Equity Research

The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.

Zacks Equity Research

Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli

by Zacks Equity Research

Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.

Zacks Equity Research

Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study

by Zacks Equity Research

Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.

Zacks Equity Research

Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?

by Zacks Equity Research

Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.

Zacks Equity Research

NextCure (NXTC) Down on Shelving Plans to Develop Candidate

by Zacks Equity Research

NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.